ViP研究评述：延长癌中之王胰腺癌的生存期，任重而道远

摘要

<正>1文献来源Middleton G,Palmer DH,Greenhalf W,et al.Vandetanib plus Gemcitabine versus placebo plusGemcitabine in locally advanced or metastaticpancreatic carcinoma (Vi P):A prospective,randomised,double-blind,multicentre phase 2 trial[J]. Lancet Oncol,2017,18(4):486-499.

关键词